Synkriom ’s Post

Data Overload in Life Sciences !! The life sciences sector faces data overload due to massive volumes of data from research, clinical trials, and patient records. This data is highly diverse, encompassing genomic, proteomic, and clinical information, and is generated at a rapid pace, necessitating real-time analysis. The complexity of these datasets poses significant challenges in integrating disparate sources and formats. Additionally, managing large volumes of data securely and efficiently remains a major concern. Ensuring data quality, including accuracy, consistency, and completeness, is critical but challenging. Analysis bottlenecks occur due to limited resources for processing and interpreting vast amounts of data. Finally, strict regulatory compliance and data privacy standards add another layer of complexity to data management in life sciences. 👉 Connect with us: https://bit.ly/3W0YNbZ 📩 contact@synkriom.com #Synkriom #AI #lifesciences #Clinicaltrails #MedicalTechnology #GenAI #patientcare #healthcare #Medicaltrails #futureofmedicine #clinicalresearch #lifesciencetrends #accuracy #compliance #digitalteam #VirtualHealthcare #Drugdiscovery #automation #drugsupplychain #drugdevelopment #diagnostic #TechAdvancements #VirtualHealthcare #HealthcareInnovation #teamsynkriom #usa

In our latest insight into AI in the #lifesciences, Vladimir Murovec and Louis Hoffreumon explain the new CE-marking regime established by the EU #AIAct. Life sciences companies sans CE-marked products must grasp new rules for high-risk AI systems they provide. Those accustomed to CE-marking must now navigate tailored regulations for AI-driven health tech.   Read more --> https://lnkd.in/g_q9-ZyP #pharma #medtech #diagnostics

Collaboration and innovation take centre stage in life science research In a gathering of nearly 300 #LifeSciences experts at the Pistoia Alliance’s largest-ever European conference, the industry spotlight shone brightly on the transformative potential of #ArtificialIntelligence (AI). However, amidst the buzz of innovation, concerns loomed over regulatory hurdles and data challenges hampering widescale adoption. Survey results unveiled a striking dichotomy: while 70% of respondents acknowledged AI's vast potential, many grappled with the practicalities of implementation, citing obstacles such as data integrity and interoperability. Dame Janet Thornton, a pioneering figure in structural bioinformatics, set the tone for collaboration with her keynote address, echoed by luminaries such as Dr Larry Callahan from the FDA and industry representatives from AbbVie, AstraZeneca, GSK and more. Dr Becky Upton, President of the Pistoia Alliance, underscored the industry's collective resolve: "As technology evolves rapidly, collaboration becomes paramount. Our London conference epitomises the Alliance's mission to foster a forum for safe, effective collaboration. Together, we can surmount the challenges and harness the full potential of AI." As the industry gears up for its next milestone, the Pistoia Alliance invites stakeholders to join forces at its upcoming member conference in Philadelphia on November 12-13. For more information on membership and registration, visit the Pistoia Alliance website. https://lnkd.in/eV-mMAFx #LifeSciencesAI #PistoiaAlliance #CollaborateToInnovate

Don't miss Dr. Daniel-Timon Spanka's presentation on our AI-software #Meteor at the 𝟭𝟯𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗛𝗼𝘂𝘀𝗲 𝗼𝗳 𝗣𝗵𝗮𝗿𝗺𝗮 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 on September 3. In clinical studies, hastily documented free text data poses challenges, impacting data quality and patient safety. Manual review of these texts is time-consuming for Data Management and Pharmacovigilance departments, requiring valuable expert time. Meteor's AI-solution blends human expertise and machine intelligence to elevate clinical data reviews. 👩⚕️🧠 Read this blog article by @Daniel-Timon Spanka to get a first look into Meteor and learn how the software improves data quality and patient safety. 🚀   Read the full article here:   ➡️ https://lnkd.in/eBGUFVc2 #Digitalization #ClinicalResearch #AI #AIInHealthcare #blog House of Pharma & Healthcare Alex Heinz Hanno Härtlein Dr. Paul W. Dr. Benedikt Linder Dr. Juan M. Guerra

🚀 Our series on the #EUAIAct in life sciences and #health care continues. In this new piece, we’re exploring the new CE-marking rules that apply to some AI systems. Life sciences companies without CE-marked products must adapt to new regulations for high-risk AI systems. Meanwhile, those familiar with CE-marking, like #medicaldevice manufacturers, face a new set of requirements tailored for AI technologies. Navigating this transition alongside existing #EU legislation will demand significant effort, especially when involving a notified body. #regulatory #pharma #medtech | Osborne Clarke, Louis Hoffreumon

No - I’m not convinced that we should be happy about these percentages. “Helping Doctors Make Tricky Diagnoses - In a JAMA study, researchers studied seven tricky cases and tested if Chat GPT-4, an AI platform, could make the diagnosis only using the case description and test results. AI correctly diagnosed the case 39% of the time and listed the correct diagnosis as a possible but not top diagnosis in 64% of cases. Those numbers may not be reassuring to patients. Yet for doctors, it shows the power of AI to copilot perplexing cases, aiding in challenging medical decision-making.” Furthermore, I’m curious to know how Ambient AI rolls up the data in raw form and what does it look like? What happens to de identified pt data (there really isn’t such a thing)? The big questions are - who’s listening and what gets incorporated into the big databases?

Healthcare analytics is revolutionizing the industry by leveraging the power of data to uncover hidden patterns and correlations in complex medical datasets. This enables a range of benefits, including: Al-driven diagnosis: Improved accuracy in diagnoses by uncovering patterns in vast amounts of medical data. Personalized care: Predicting patient responses to personalize treatment paths for better outcomes. Proactive detection: Early identification of health risks through AI-powered data analysis. Faster drug development: Accelerated research and development by simulating and predicting the effectiveness of new drugs. How is your healthcare organization leveraging data analytics to improve patient care? #atgeirsolutions #generativeai #ai

Hey Connections!! I have some Exciting news to share! Introducing my latest project on RAG implementation for medical Question Answering 🩺 The global healthcare AI market is projected to soar to billions by 2025, driven by the burgeoning demand for AI-powered solutions in medical imaging, drug discovery, and patient data analysis. The quest to personalize medical care and interventions based on individual genetic, environmental, and lifestyle factors holds immense promise for enhancing patient outcomes and healthcare efficiency 🔬. In recent years, Large Language Models (LLMs) have showcased remarkable adaptability, presenting boundless opportunities across specialized domains like healthcare and medicine. I am thrilled to unveil the developed healthcare-based question-answering system. Leveraging BioMistral 7B as the foundation, seamless integration of PubMedBert for embeddings, Qdrant for a self-hosted Vector DB, and orchestrated it all with Langchain & Llama CPP frameworks. 🧬 Join me in spearheading the revolution in healthcare domain using state-of-the-art open-source tools! Thank You!! #MedicalQA #OpenSource #Bioinformatics #HealthTech #ArtificialIntelligence #Langchain #RAG

"Life sciences companies have access to a vast amount of patient and health care provider (HCP) data to meet regulatory compliance and operational needs. Yet many organizations are underutilizing these rich and valuable datasets, failing to extract actionable insights thatcan fuel product development and sustain competitive advantage." (Deloitte; "Patient and HCP data can influence life sciences and health care product development") #biopharma #ai #genai

Given the increasing impact of #AI on our lives, effective regulation is needed to boost the use of AI-based technologies in clinical care and diagnostics. Read Corinne Dive-Reclus, Global Head of Digital Diagnostics at Roche, views on the need for a legal and ethical regulatory framework to support the use of AI-based applications for the benefit of patient well-being. 📰 https://bit.ly/3Sr6olb